Penem prodrug
AssigneePfizer Inc.
InventorsKatherine Elizabeth Brighty, Anthony Marfat, Dale Gordon McLeod, John P. O'Donnell, Stephen R. Anderson
Life of this patent
Estimating the term…
Abstract
The invention relates to prodrugs of sulopenem of formula (I): wherein R1 is —(C2-C8)alkyl, or a solvate or hydrate thereof. The invention also relates to the preparation, formulation, and use of the prodrugs of sulopenem to treat a disorder such as an infection in a patient in need thereof.
Claims19
A compound of formula (I):
- wherein R1 is —(CH2C8)alkyl, or a solvate or hydrate thereof.
The method of 9, wherein said bacterial infection is a gram-negative infection except for Pseudomonas aeruginosa, Acinetobacter spp. and Stenotrophomonas maltophilia.
The compound (5-propyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate.
The compound (5-(3-methylpropyl)-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate.
Dependencies are inferred from the claim text.